An Open-Label Two-Part Randomized, Crossover Study Of The Pharmacokinetics Of CE-224,535 Administered As Modified And Immediate Release Formulations In Healthy Volunteers

Trial Profile

An Open-Label Two-Part Randomized, Crossover Study Of The Pharmacokinetics Of CE-224,535 Administered As Modified And Immediate Release Formulations In Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs CE 224535 (Primary)
  • Indications Osteoarthritis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Apr 2009 Planned number of patients changed from 24 to 11 as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top